362 related articles for article (PubMed ID: 25504326)
1. Developmental insights into the pathology of and therapeutic strategies for DM1: Back to the basics.
Chau A; Kalsotra A
Dev Dyn; 2015 Mar; 244(3):377-90. PubMed ID: 25504326
[TBL] [Abstract][Full Text] [Related]
2. Sense and Antisense DMPK RNA Foci Accumulate in DM1 Tissues during Development.
Michel L; Huguet-Lachon A; Gourdon G
PLoS One; 2015; 10(9):e0137620. PubMed ID: 26339785
[TBL] [Abstract][Full Text] [Related]
3. Systemic delivery of a Peptide-linked morpholino oligonucleotide neutralizes mutant RNA toxicity in a mouse model of myotonic dystrophy.
Leger AJ; Mosquea LM; Clayton NP; Wu IH; Weeden T; Nelson CA; Phillips L; Roberts E; Piepenhagen PA; Cheng SH; Wentworth BM
Nucleic Acid Ther; 2013 Apr; 23(2):109-17. PubMed ID: 23308382
[TBL] [Abstract][Full Text] [Related]
4. Reduced cytoplasmic MBNL1 is an early event in a brain-specific mouse model of myotonic dystrophy.
Wang PY; Lin YM; Wang LH; Kuo TY; Cheng SJ; Wang GS
Hum Mol Genet; 2017 Jun; 26(12):2247-2257. PubMed ID: 28369378
[TBL] [Abstract][Full Text] [Related]
5. An Overview of Alternative Splicing Defects Implicated in Myotonic Dystrophy Type I.
López-Martínez A; Soblechero-Martín P; de-la-Puente-Ovejero L; Nogales-Gadea G; Arechavala-Gomeza V
Genes (Basel); 2020 Sep; 11(9):. PubMed ID: 32971903
[TBL] [Abstract][Full Text] [Related]
6. Systemic Evaluation of Chimeric LNA/2'-O-Methyl Steric Blockers for Myotonic Dystrophy Type 1 Therapy.
Christou M; Wengel J; Sokratous K; Kyriacou K; Nikolaou G; Phylactou LA; Mastroyiannopoulos NP
Nucleic Acid Ther; 2020 Apr; 30(2):80-93. PubMed ID: 31873063
[TBL] [Abstract][Full Text] [Related]
7. Short antisense-locked nucleic acids (all-LNAs) correct alternative splicing abnormalities in myotonic dystrophy.
Wojtkowiak-Szlachcic A; Taylor K; Stepniak-Konieczna E; Sznajder LJ; Mykowska A; Sroka J; Thornton CA; Sobczak K
Nucleic Acids Res; 2015 Mar; 43(6):3318-31. PubMed ID: 25753670
[TBL] [Abstract][Full Text] [Related]
8. Fuchs' Endothelial Corneal Dystrophy and RNA Foci in Patients With Myotonic Dystrophy.
Mootha VV; Hansen B; Rong Z; Mammen PP; Zhou Z; Xing C; Gong X
Invest Ophthalmol Vis Sci; 2017 Sep; 58(11):4579-4585. PubMed ID: 28886202
[TBL] [Abstract][Full Text] [Related]
9. Myotonic dystrophies: An update on clinical aspects, genetic, pathology, and molecular pathomechanisms.
Meola G; Cardani R
Biochim Biophys Acta; 2015 Apr; 1852(4):594-606. PubMed ID: 24882752
[TBL] [Abstract][Full Text] [Related]
10. In vivo co-localisation of MBNL protein with DMPK expanded-repeat transcripts.
Fardaei M; Larkin K; Brook JD; Hamshere MG
Nucleic Acids Res; 2001 Jul; 29(13):2766-71. PubMed ID: 11433021
[TBL] [Abstract][Full Text] [Related]
11. A CTG repeat-selective chemical screen identifies microtubule inhibitors as selective modulators of toxic CUG RNA levels.
Reddy K; Jenquin JR; McConnell OL; Cleary JD; Richardson JI; Pinto BS; Haerle MC; Delgado E; Planco L; Nakamori M; Wang ET; Berglund JA
Proc Natl Acad Sci U S A; 2019 Oct; 116(42):20991-21000. PubMed ID: 31570586
[TBL] [Abstract][Full Text] [Related]
12. Transcriptome Analysis Reveals Altered Inflammatory Pathway in an Inducible Glial Cell Model of Myotonic Dystrophy Type 1.
Azotla-Vilchis CN; Sanchez-Celis D; Agonizantes-Juárez LE; Suárez-Sánchez R; Hernández-Hernández JM; Peña J; Vázquez-Santillán K; Leyva-García N; Ortega A; Maldonado V; Rangel C; Magaña JJ; Cisneros B; Hernández-Hernández O
Biomolecules; 2021 Jan; 11(2):. PubMed ID: 33530452
[TBL] [Abstract][Full Text] [Related]
13. Antisense transcription of the myotonic dystrophy locus yields low-abundant RNAs with and without (CAG)n repeat.
Gudde AEEG; van Heeringen SJ; de Oude AI; van Kessel IDG; Estabrook J; Wang ET; Wieringa B; Wansink DG
RNA Biol; 2017 Oct; 14(10):1374-1388. PubMed ID: 28102759
[TBL] [Abstract][Full Text] [Related]
14. Myotonic dystrophy type 1: role of CCG, CTC and CGG interruptions within DMPK alleles in the pathogenesis and molecular diagnosis.
Santoro M; Masciullo M; Silvestri G; Novelli G; Botta A
Clin Genet; 2017 Oct; 92(4):355-364. PubMed ID: 27991661
[TBL] [Abstract][Full Text] [Related]
15. Quantitative Methods to Monitor RNA Biomarkers in Myotonic Dystrophy.
Wojciechowska M; Sobczak K; Kozlowski P; Sedehizadeh S; Wojtkowiak-Szlachcic A; Czubak K; Markus R; Lusakowska A; Kaminska A; Brook JD
Sci Rep; 2018 Apr; 8(1):5885. PubMed ID: 29651162
[TBL] [Abstract][Full Text] [Related]
16. Staufen1 Regulates Multiple Alternative Splicing Events either Positively or Negatively in DM1 Indicating Its Role as a Disease Modifier.
Bondy-Chorney E; Crawford Parks TE; Ravel-Chapuis A; Klinck R; Rocheleau L; Pelchat M; Chabot B; Jasmin BJ; Côté J
PLoS Genet; 2016 Jan; 12(1):e1005827. PubMed ID: 26824521
[TBL] [Abstract][Full Text] [Related]
17. (CTG)n repeat-mediated dysregulation of MBNL1 and MBNL2 expression during myogenesis in DM1 occurs already at the myoblast stage.
André LM; van Cruchten RTP; Willemse M; Wansink DG
PLoS One; 2019; 14(5):e0217317. PubMed ID: 31116797
[TBL] [Abstract][Full Text] [Related]
18. Expanded CUG repeats in
van Cruchten RTP; Wieringa B; Wansink DG
RNA; 2019 Apr; 25(4):481-495. PubMed ID: 30700578
[TBL] [Abstract][Full Text] [Related]
19. Gain of RNA function in pathological cases: Focus on myotonic dystrophy.
Klein AF; Gasnier E; Furling D
Biochimie; 2011 Nov; 93(11):2006-12. PubMed ID: 21763392
[TBL] [Abstract][Full Text] [Related]
20. AON-induced splice-switching and DMPK pre-mRNA degradation as potential therapeutic approaches for Myotonic Dystrophy type 1.
Stepniak-Konieczna E; Konieczny P; Cywoniuk P; Dluzewska J; Sobczak K
Nucleic Acids Res; 2020 Mar; 48(5):2531-2543. PubMed ID: 31965181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
